[ad_1]
A New analysis reveals that clinical trials conducted by Biogen (BIIB) for its controversial treatment for Alzheimer’s disease would have excluded up to 92% of Medicare beneficiaries – a key part of the targeted patient population – based on their age or their existing medical conditions.
In summary, a total of 92% of patients with Alzheimer’s disease and related disorders, 91% with Alzheimer’s disease in particular, and 85.5% of patients with mild cognitive impairment responded to at least one of the study exclusion criteria, based on review published in JAMA. . The most common criteria were heart disease, conditions associated with blood clots, chronic kidney disease, and age 85 or older. Most people actually met more than two of the criteria used to exclude participants.
Unlock this article by subscribing to STAT + and enjoy your first 30 days free!
TO START
What is that?
STAT + is STAT’s premium subscription service for in-depth coverage and analysis of biotechnology, pharmaceuticals, policy and life sciences. Our award-winning team covers news from Wall Street, political developments in Washington, early scientific breakthroughs and clinical trial results, as well as healthcare disruptions in Silicon Valley and beyond.
What is included?
- Daily reporting and analysis
- Industry’s most comprehensive coverage from a powerful team of journalists
- Newsletters reserved for subscribers
- Daily newsletters to keep you informed of the most important industry news of the day
- STAT + conversations
- Weekly opportunities to engage with our journalists and leading industry experts in live video chats
- Exclusive industry events
- Premium access to subscriber-only networking events nationwide
- The best reporters in the industry
- The most reliable and most connected newsroom in the healthcare industry
- And much more
- Exclusive interviews with industry leaders, profiles and premium tools, like our CRISPR Trackr.
[ad_2]
Source link